Monopar Therapeutics Inc (MNPR NASDAQ) stock market data APIs
$69.7252
-2.45(-3.5%)
as of November 3, 2026
Try our APIs with
free plan!
Monopar Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Prev. Close
69.7252
Open
67.274
High
70.0828
Low
66.1636
52 wk Range
50.07-124.82
Market Cap
469 M
Shares Outstanding
6 712 K
EPS
-0.62
Beta
1.615
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Monopar Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Monopar Therapeutics Inc data using free add-ons & libraries
Get Monopar Therapeutics Inc Fundamental Data
Monopar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Monopar Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monopar Therapeutics Inc News
New
Monopar Q2 Net Loss Widens; Rolling NDA Submission For ALXN1840 In Wilson Disease Underway
(RTTNews) - Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss, and provided an update...
Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX
(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc....
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studie...
Monopar Therapeutics Granted Rare Pediatric Disease Designation To ALXN1840 To Treat Wilson Disease
(RTTNews) - Biopharmaceutical company Monopar Therapeutics, Inc. (MNPR) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1...
Get Monopar Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.